Q4 2022

Filed Apr 17, 2023 · 10-K · 107 days after period end · 0001410578-23-000698

Q4 2022 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—

Net Income

$2.61M

derivedno prior Q4 2021 on file

EPS, diluted—Not derived. Share counts vary by quarter.

Operating Cash Flowderived-$13,861—

Same quarter

no prior Q4 2021 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Dec 31, 2022 · filed Apr 17, 2023 · 107 d after period end

Tevogen Inc. · CIK 1860871 · Engraved from SEC EDGAR